CAS: 40296-46-6; Ethyl 4,6-Dichloronicotinate

相似化合物

73027-79-9 1060811-62-2 73998-95-5

上下游产品

CAS号6975-44-6 4,6-二羟基烟酸乙酯 | CAS号105-50-0 丙酮二羧酸二乙酯 | CAS号73027-79-9 4,6-二氯烟酸 | CAS号141-52-6 乙醇钠 | CAS号107836-75-9 4,6-二氯烟酰氯 | CAS号107836-75-9 4,6-二氯烟酰氯 | CAS号405230-82-2 2,5-二氯-4-氨基吡啶 | CAS号449811-29-4 6-氯-4-(甲基氨基)烟醛 | CAS号28443-69-8 2,3,5-三氯-4-氨基吡啶 | CAS号821791-58-6 4-氯-1-甲基-6-氧代-1... | CAS号73998-95-5 (4,6-二氯吡啶-3-基)甲醇 | CAS号7321-93-9 2,4-二氯-5-氨基吡啶 | CAS号73027-79-9 4,6-二氯烟酸 | CAS号166526-03-0 4,6-二氯烟腈 | CAS号449811-28-3 6-氯-4-(甲基氨基)烟酸乙酯

4,6-二羟基烟酸乙酯置于三氯氧磷体系中,化学反应 24.0H,以71%的收率获得产物4,6-二氯烟酸乙酯
参考文献:喹诺酮酰胺为具有体内活性的抗胰头体前导化合物.
标题:喹诺酮酰胺为具有体内活性的抗胰头体前导化合物.
摘要:人类非洲锥虫病(hat)是一种主要的热带疾病,几乎没有可用于治疗的药物,从而推动了对新型活性化合物的需求.最近,氟喹诺酮类抗生素的吗啉代取代的苄基酰胺被确定为对布鲁氏锥虫具有高活性的化合物.由于先导化合物ghq168在先前的试验中受到水溶性差的挑战,因此本研究的目的是引入结构变异性ghq168以及配制ghq168的最终目的是增加其水溶性,同时保持其体外抗锥虫活性.喷雾干燥的ghq168以及新合成的化合物ghq242和ghq243在小鼠体内的药代动力学参数的特征是消除半衰期为1.5到3.腹膜内给药5小时后(4只小鼠/化合物),人血清白蛋白对ghq168(80%)和ghq243(45%)的结合具有中等至强的结合力,而ghq242对人血清白蛋白的结合非常高(＞ 99%).对于铅化合物ghq168,表观清除率为112 Ml / H,表观分布体积为14升/ Kg体重(bw).感染了t的小鼠.b.在严
DOI:10.1128/aac.01757-15

专利信息

专利号:US-7897762-B2
优先权日:2006-09-14
标 题:Kinase inhibitors useful for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:DECIPHERA PHARMACEUTICALS LLC
摘要:The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-2025026766-A1
优先权日:2022-01-12
标题 :Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors
发明人：LI JING; XU WENQING; WANG ZHIWEI
权利人:BEIGENE LTD
摘要:The present invention relates to compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including cancers.

专利号:CN-109651241-B
优先权日:2018-12-27
标题 :Synthesis method of 4-bromo-6-chloronicotinaldehyde